Ladostigil is a dual cholinesterase (ChE) and brain-selective monoamine oxidase-A (MAO-A) and monoamine oxidase-B (MAO-B) inhibitor, indicated for the treatment of dementia, comorbid with extrapyramidal disorders and depression. Here, MAOB is linked to depressive symptom measurement.